申请人:Gilbert Eric J.
公开号:US20090105208A1
公开(公告)日:2009-04-23
Compounds of Formula (I):
or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB
1
receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
式(I)的化合物或其药学上可接受的盐、溶剂化物或酯类,可用于治疗由CB1受体介导的疾病或症状,例如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾(例如戒烟)、胃肠疾病和心血管疾病。